Merus (MRUS) said late Thursday that interim data from a phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab showed "robust" efficacy and durability as a first-line treatment of PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma.
Based on a Feb. 27 cutoff, the data showed a 63% overall response rate in 43 evaluable patients, including six complete responses, as well as a 79% survival rate at 12-months, according to the company.
"By essentially every metric, we believe these interim data are significantly better than pembrolizumab monotherapy, the control arm of our ongoing phase 3 trial, and underscores the opportunity petosemtamab holds to become a new standard of care, if approved, in head and neck cancer," Chief Executive Bill Lundberg said.
The company plans to share top line interim readout of one or both of its phase 3 trials next year, Lundberg said.
Merus shares were up 8.9% in recent premarket activity Friday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。